Global Blood Therapeutics Announces Upcoming Investor Webcasts Including Event to Highlight GBT440 Data in Sickle Cell Disease at ASH

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced two upcoming investor webcasts. 

• On Monday, December 7 at 12:30 p.m. Eastern Time (ET), members of GBT’s management team and distinguished expert, Dr. Claire Hemmaway, MA (Hons) Cantab, MBBS, FRCP, FRCPATH, Queens Hospital, Essex, United Kingdom, will review the GBT440 data to be presented at the 57^th American Society of Hematology (ASH) Annual Meeting and Exposition.
   
• On Tuesday, December 8, at 9:10 a.m. ET Ted W. Love, M.D., GBT’s chief executive officer, will present at the Oppenheimer 26^th Annual Healthcare Conference.

The presentations will be webcast live and will be available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF) and hereditary angioedema (HAE). To learn more, please visit: www.globalbloodtx.com.

Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. We intend these forward-looking statements, including statements regarding the therapeutic potential of GBT440 and any other product candidates that we may identify and develop, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, those set forth in the prospectus for our initial public offering of common stock that was filed with the U.S. Securities and Exchange Commission (the "SEC") on August 12, 2015, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information: 
Joey Fleury (investors) 
BrewLife
415-946-1090 
[email protected]

Ryan Flinn (media) 
BrewLife 
415-946-1059
[email protected]